1. Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
- Author
-
Ngo, Dat, Tinajero, Jose, Li, Shanpeng, Palmer, Joycelynne, Pourhassan, Hoda, Aribi, Ahmed, Nakamura, Ryotaro, Stein, Anthony, Marcucci, Guido, Salhotra, Amandeep, Sandhu, Karamjeet, Pullarkat, Vinod, Ball, Brian, and Koller, Paul
- Subjects
ACUTE myeloid leukemia ,VENETOCLAX ,HEMATOPOIETIC stem cells ,STEM cell transplantation ,PROTEIN-tyrosine kinases - Abstract
Relapsed or refractory (R/R) acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutations remains a difficult and hard to treat entity. Gilteritinib is a potent oral FLT-3 inhibitor that improves overall survival in R/R AML, but studies are limited in combining gilteritinib with a hypomethylating agent and venetoclax treatment backbone (HMA-VEN-GILT). Here we report our experience with HMA-VEN-GILT for 22 R/R FLT3 AML patients. HMA-VEN-GILT yielded an ORR of 77.3% (17/22), CR 4.5% (1/22), CRi 13.6% (3/22), MLFS 59.1% (13/22). Median follow-up was 10.4 months with a relapse rate of 29.4% (5/17), median time to relapse of 69 days (range 35–298 days), 6-month overall survival of 84%, and median OS of 10.1 months. Additionally, 36.4% (8/22) of patients proceeded to hematopoietic stem cell transplant. In conclusion, HMA-VEN-GILT for the treatment of R/R FLT3 AML is feasible and can be used as a bridge to allogeneic transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF